Biomerica : Investor Presentation

Investor Presentation

M a y 2 0 2 4

Forward-Looking Statement

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this presentation (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, including statements not of historical fact; such as statements relating to - intended launch dates, sales potential, product benefits, market size, number of sufferers with IBS, prospects, new products, favorable outlook, market competition, anticipated or possible future revenues including InFoods® technology revenue opportunities, the regulatory pathway to FDA clearance, probability of FDA or other regulatory clearances, insurance reimbursement availability and amounts, physician adoption rates, efficacy and pricing of competing products, patent protection of the InFoods® technology, production volume of the Company's products, and the launch or success of current and new product offerings; as well as statements relating to the Company's products including; the efficacy of InFoods IBS at treating IBS symptoms in patients, accuracy of the InFoods product at detecting correct foods causing patient IBS symptoms, results of studies testing the Company's products' efficacy and accuracy, FDA clearance timing and requirements, EU clearance including CE Mark, the rapidity of testing results, uniqueness of these tests, use and commercial adoption of the Company's tests, pricing of the Company's test kits, domestic and international demand and orders, the Company's manufacturing capacity, patent protection, and all regulatory approvals necessary prior to commercialization of the Company's tests; and, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; competition from other similar products and from competitors that have significantly more financial and other resources available; and any other aspect of the Company's tests and products. Such forward- looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Forward looking statements also include the assumptions underlying or relating to such statements. The underlying assumptions could prove to be inaccurate or known or unknown risks or uncertainties could materialize, therefore actual results could vary materially. The potential risks and uncertainties include, among others, fluctuations in the Company's operating results, downturns in international and or national economies, the Company's ability to raise additional capital as needed, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships and on regulatory approvals. A further list and description of these risks, uncertainties and other factors can be found in our report on Form 10-K filed with the Securities and Exchange Commission on August 29, 2022. Any forward-looking statements made in this presentation speak only as of the date of the presentation. The Company is under no obligation to update any forward-looking statements after the date of this presentation.

Copyright © 2024 Biomerica. All Rights Reserved 2

Who We Are

Depth of Scientific Leadership

US Members of the Rome Foundation Clinical studies lead by principal investigators who set GI "treatment guidelines"

Large-scale Device

Manufacture

Production of products in GI and areas at 2 facilities

2 FDA, CE, CFDA registered manufacturing facilities in California and Mexico Headquarter: Irvine, CA, USA

Global Biomedical Company

Develops, patents, manufactures & markets advanced diagnostics for use in Clinical lab, Point-of-Care,At-Home

Contract Manufacturer

For 2 multinational pharma companies, Bio-Rad & other leading organization

Experienced Manufacturer of FDA cleared & CE marked products

Our customers

in USA

Copyright © 2024 Biomerica. All Rights Reserved 3

Leadership, Board & Depth in Science

Management

ZACK IRANI

• Chief Executive Officer & Chairman
• Previous CEO & Chairman of Lancer Orthodontics Inc.

ALLEN BARBIERI

• Executive Vice Chairman
• Previous CEO of numerous public and private companies

ROBERT CARLSON

• Chief Commercial Officer
• Previous CCO of Prometheus Laboratories , a Nestle Health Science Company

Independent BOD Members

Cathy Coste, CPA

Former Deloitte Partner

Jane Emerson, MD, PhD

Chief of Clinical Pathology, USC

David Moatazedi

CEO Evolus (NASDAQ: EOLS)

Scientific Advisory Board

Principal

Investigators or

Collaborators for:

DOUGLAS DROSSMAN, MD

• President Emeritus,

Rome Foundation

• Co-DirectorEmeritus, UNC Center for Functional GI and Motility Disorders

LIN CHANG, MD

• Professor of Medicine, UCLA, Division

of Digestive Diseases

• Rome Board member
• Served on FDA GI advisory panel

WILLIAM CHEY, MD, AGAF,

FACG, FACP

• Professor GI & Nutrition Sciences, Univ. of Michigan
• Rome Board member
• Co-DirectorMichigan Bowel Program

BRIAN LACY, MD, PHD

• Mayo Clinic
• Co-Authorof ACG Guidelines

ANTHONY LEMBO, MD

• Harvard Medical & Beth Israel Deaconess Medical Center
• Associate Editor of Journal of Clinical Gastroenterology and Digestive Diseases and Science

InFoods® Principal Investigators

WILLIAM CHEY, MD, AGAF,

FACG, FACP

• University of Michigan - Ann Arbor
• Director of the Digestive Diseases Center
• Co-Authorof ACG Guidelines

ANTHONY LEMBO, MD

• Harvard - Beth Israel Deaconess

Medical Center

TISHA LUNSFORD, MD

• Mayo Clinic
• Director of the Motility Interest Group

BRIAN LACY, MD, PHD

• Mayo Clinic
• Current co-Editor in Chief of the American Journal of Gastroenterology
• Co-Authorof ACG Guidelines

EAMONN QUIGLEY, MD

• Chief, Division of Gastroenterology and Hepatology at Houston Methodist

BROOKS CASH, MD, AGAF, FACG,

FACP, FASGE

• Chief of Gastroenterology, University of Texas Health Science Center at Houston

Copyright © 2024 Biomerica. All Rights Reserved 4

Background & Innovation

Leveraging diagnostic expertise to transition into diagnostic-guided therapeutics

Specialty diagnostics enabling early

disease detection and monitoring

Two FDA, CE, CFDA registered manufacturing facilities in California and Mexico

Commercially launched FDA cleared diagnostic tests

Disruptive patented technology platform enabling diagnostic therapies

Redefining the treatment of GI diseases

Also applicable for treating non-GI chronic inflammatory diseases

Gross margin opportunities similar to drugs

Copyright © 2024 Biomerica. All Rights Reserved 5

InFoods® - Diagnostic Guided Therapy (DGT) Personalize Medicine for IBS patients

Example of Patient-Specific Results

FDA-regulated diagnostic to be used as therapy

Measures immunoreactivity for a panel of foods to determine which foods are above normal range and problematic for a specific patient

Allows physicians to identify patient-specific foods which, when removed from diet, may alleviate or improve the patient's gastrointestinal symptoms and suffering

Clinical trial guided by U.S. members of the Rome Foundation, the leading organization that sets IBS treatment guidelines

Note: Clinical lab product in clinical studies.

Copyright © 2024 Biomerica. All Rights Reserved 6

Irritable Bowel Syndrome (IBS) is Very Common and Costly

IBS is the #1 most common

diagnosis made by gastroenterologists1

IBS patients visit doctors 3x more than non-IBS patients

IBS is the #7 most common diagnosis made by

all physicians1

IBS sufferers have 74% more direct healthcare costs vs. non-IBS sufferers

The Majority of IBS patients believe foods trigger their symptoms

1Recent AGA Survey (American Gastroenterological Association).

Copyright © 2024 Biomerica. All Rights Reserved 7

IBS Market is Significant Today and Growing

$30B+

U.S. TAM1

	M
	Million
D	C 40 IBS Patients in the US

1/3 IBS-C	1/3 IBS-D	1/3 IBS-M (Mixed:
(Constipation)	(Diarrhea)	Alternates C+D)

IBS = recurrent abdominal pain & change in bowel habits

~16 US IBS Patients: seeking consistent

M I L L I O N physician treatment

~13	No approved
	IBS-M Patients:
M I L L I O N	therapy/drug2

1Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis.Clinical gastroenterology and hepatology. 2012 Jul 1;10(7):712-21.

2Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Alimentary pharmacology & therapeutics. 2005 Jun;21(11):1365-75.

Copyright © 2024 Biomerica. All Rights Reserved 8

Clinical Study

Copyright © 2024 Biomerica. All Rights Reserved 9

InFoods® IBS: Clinical Trial Design Summary

Randomized Double Blinded

Placebo controlled

Food consumption survey

Patient is InFoods positive to:

Blueberries & Almonds

Treatment Arm

Placebo Arm

1 : 1

Eliminates	Eliminates
Blueberries & Almonds	Raspberries & Walnuts
	(if negative and same consumption)

Copyright © 2024 Biomerica. All Rights Reserved 10